48
Participants
Start Date
May 1, 2018
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
Aflibercept Injection [Eylea]
Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
St. Joseph's Healthcare Hamilton, Hamilton
McMaster University
OTHER